HOUSTON--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today showcased its comprehensive offering of specialty diagnostics products and analytical instruments designed to improve accuracy and productivity in clinical applications. The Thermo Scientific solutions are on display in booth 5140 during the Clinical Lab Expo at the American Association for Clinical Chemistry(AACC) conference, being held at the George R. Brown Convention Center in Houston from July 30 - August 1.

“Clinical laboratories are playing an ever-increasing role in supporting the diagnosis and monitoring of disease,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “Our goal is to develop new technologies and diagnostic tests that enable physicians to deliver better patient care at a lower cost.”

Better Tests for Informed Clinical Decisions

Thermo Fisher announced that its new Thermo Scientific QMS Tacrolimus immunoassay, unveiled at AACC last year, has received 510(k) clearance by the U.S. Food and Drug Administration. The liquid, ready-to-use immunoassay measures levels of tacrolimus on automated clinical chemistry analyzers, including the bench-top Thermo Scientific Indiko analyzer, to improve the quality of life for kidney, liver, and heart transplant patients.

The company also marked the debut of another FDA-cleared product, the Thermo Scientific MAS Omni•CARDIO controls, an assayed control serum comprising a combination of cardiac and associated critical markers for use in clinical laboratories to monitor assay conditions. The single test eliminates the need for separate quality control measures between tests and provides rapid results.

Leading Portfolio of Tools for Research Use Only

The new Thermo Scientific Sorvall ST 8 centrifuge reduces potential bottlenecks in the laboratory through its flexible, user-friendly design. The small bench-top centrifuge offers easy rotor exchange, an ability to spin several types of tubes simultaneously and integration with other tools, including microplates.

This year also marks the AACC introduction of Thermo Fisher’s landmark new offerings in chromatography and mass spectrometry. Its Thermo Scientific Prelude SPLC sample preparation and liquid chromatography system, combined with the new workhorse Thermo Scientific TSQ Endura triple-stage quadrupole mass spectrometer, provides the performance necessary for analysis of target compounds in complex biological matrices. The resulting workflow is easy to manage making LC-MS more widely accessible in clinical research laboratories.

For more information on new products introduced at AACC, please visit Thermo Scientific booth 5140 or the online media room at www.thermofisher.com/news.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $13 billion, we have 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit www.thermofisher.com.

Contact: